Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 15/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19471156 | 1.00 | RIPK1 (1.00) | RIPK1SMN1; SMN2SIGMAR1 | |
| SCHEMBL17881916 | 0.87 | RIPK1 (0.78) | RIPK1 | |
| SCHEMBL19512298 | 0.86 | RIPK1 (0.74) | RIPK1SIGMAR1 | |
| SCHEMBL17881983 | 0.86 | RIPK1 (0.74) | RIPK1SMN1; SMN2 | |
| SCHEMBL19471206 | 0.83 | RIPK1 (0.71) | RIPK1SMN1; SMN2SIGMAR1 | |
| SCHEMBL17881887 | 0.83 | RIPK1 (0.70) | RIPK1 | |
| SCHEMBL17881915 | 0.82 | RIPK1 (0.68) | RIPK1SMN1; SMN2 | |
| SCHEMBL19471194 | 0.81 | RIPK1 (0.67) | RIPK1SMN1; SMN2 | |
| SCHEMBL19471108 | 0.81 | RIPK1 (1.00) | RIPK1SMN1; SMN2 | |
| SCHEMBL17881991 | 0.81 | RIPK1 (0.67) | RIPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3612223-B1 | TREATING MALE SENESCENCE | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2024-07-31 | — | — | EP | claimed |
| CN-110769853-B | Treatment of male aging | 北京生命科学研究所 | 2022-06-03 | — | — | CN | claimed |
| US-11090307-B2 | Treating male senescence | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-08-17 | — | — | US | claimed |
| CN-110769853-A | Treatment of male aging | 北京生命科学研究所 | 2020-02-07 | — | — | CN | claimed |
| EP-3612223-B1 | TREATING MALE SENESCENCE | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2024-07-31 | — | — | EP | disclosed |
| CN-117320754-A | Prostatitis treatment | 北京生命科学研究所 | 2023-12-29 | — | — | CN | disclosed |
| US-11478438-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2022-10-25 | — | — | US | disclosed |
| US-20220288077-A1 | PROSTATITIS TREATMENT | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES (CN) | 2022-09-15 | — | — | US | disclosed |
| EP-4017535-A1 | PROSTATITIS TREATMENT | National Institute Of Biological Sciences, Beijing (CN) | 2022-06-29 | — | — | EP | disclosed |
| CN-110769853-B | Treatment of male aging | 北京生命科学研究所 | 2022-06-03 | — | — | CN | disclosed |
| US-11090307-B2 | Treating male senescence | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-08-17 | — | — | US | disclosed |
| US-11090307-B2 | Treating male senescence | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-08-17 | — | — | US | disclosed |
| US-20190038578-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2019-02-07 | — | — | US | disclosed |
| US-20190038578-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2019-02-07 | — | — | US | disclosed |
| US-10092529-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2018-10-09 | — | — | US | disclosed |
| EP-3224245-B1 | NECROSIS INHIBITORS | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2018-09-12 | — | — | EP | disclosed |
| US-20170304237-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2017-10-26 | — | — | US | disclosed |
| US-20170304237-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2017-10-26 | — | — | US | disclosed |
| US-20170304237-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2017-10-26 | — | — | US | disclosed |
| WO-2016101887-A1 | NECROSIS INHIBITORS | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304237-A1 | Necrosis Inhibitors | RIPK3, RIPK1, RIPK4 | RIPK1 2/4885SMN1; SMN2 1120/4885SIGMAR1 1517/4885 |
| US-11478438-B2 | Necrosis inhibitors | RIPK3, RIPK1, RIPK4 | RIPK1 2/4885SMN1; SMN2 1593/4885SIGMAR1 1782/4885 |
| US-11090307-B2 | Treating male senescence | RIPK3, RIPK1, MLKL | RIPK1 2/4885SMN1; SMN2 3768/4885SIGMAR1 4777/4885 |
| US-20190038578-A1 | Necrosis Inhibitors | RIPK3, RIPK1, RIPK4 | RIPK1 2/4885SMN1; SMN2 1593/4885SIGMAR1 1782/4885 |
| US-10092529-B2 | Necrosis inhibitors | RIPK3, RIPK1, RIPK4 | RIPK1 2/4885SMN1; SMN2 1120/4885SIGMAR1 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.